Alnylam Pharmaceuticals
Top View
- Faculty Disclosure
- Download the PDF Version
- POS) Requirements for Agents That Are Not Subject to Prior Authorization
- Investor Biotech Deep Dive Boston Reflections from Visiting Selected Companies and the Unique Biotech Hub
- ALNYLAM PHARMACEUTICALS, INC. Form 10-K Annual Report Filed
- Index Components (PDF)
- DIA/FDA Oligonucleotide-Based Therapeutics Conference October 28-30 | Bethesda North Marriott Hotel | North Bethesda, MD
- Life Sciences, High Tech, and Clean Energy Companies
- The Patent Landscape of Sirna Nanoparticle Delivery
- NEDMDG 2019 Summer Symposium Table of Contents 2019 Summer Symposium Agenda
- Gateway Equity Call Premium Fund Investments As of July 31, 2021 (Unaudited)
- Faculty Disclosure
- Alnylam Pharmaceuticals, Inc. Annual Report 2018
- A Market Access Case Study for Rnai Therapeutics
- Partnering to Improve Vision AMD, Age-Related Macular Degeneration; Enac,Epithelialsodiumchannel;IGF-1R, Insulin-Like Growth Factor 1Receptor; N/A, Notavailable
- Corporate Strategies Fact File: Coronavirus Pipeline and Corporate Updates
- CY 2020 CDER Drug and Biologic Calendar Year Priority Approvals As of December 31, 2020
- Current Sustaining Member Companies